Life Sciences INDUSTRIES

The life sciences industry is a significant part of our firm's practice. WilmerHale has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for four decades. As a result, we understand the business of our life sciences clients and the regulatory, competitive and consumer demands that the industry is currently confronting.

We represent public and private companies, investment banks and venture capitalists in all aspects of the life sciences industry, including:

  • Corporate finance
  • Licensing and alliances
  • Mergers and acquisitions
  • Patent prosecution and other intellectual property matters
  • Patent, product liability, securities and other litigation
  • FDA, competition and other regulatory matters
  • Real estate

More than 100 of our lawyers devote a significant portion of their practice to these industries. Many of these lawyers have advanced degrees in relevant scientific disciplines. Some of our previous experience can be viewed here.

As a result of our skill and experience in the life sciences field, we have received many accolades, including:

  • Chambers Global 2013 recognized WilmerHale as a leader in life sciences with an "outstanding US practice coupled with international reach."
  • PLC Life Sciences Industry Super League 2012 named WilmerHale among the top ten law firms for having "a strong transatlantic life sciences practice."
  • PLC Cross-border Life Sciences Handbook 2011/12, 2009/10, 2008/09, 2007/08 and 2006/07 named WilmerHale a leading law firm in the area of life sciences.
  • Chambers USA 2013, 2012, 2011, 2010, 2009, 2008 and 2007 recognized our nationwide practice as a leader in life sciences.
  • In January 2012, The American Lawyer recognized WilmerHale as Intellectual Property Litigation Department of the Year Finalist.

The life sciences industry is a significant part of our firm's practice. WilmerHale has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for four decades. As a result, we understand the business of our life sciences clients and the regulatory, competitive and consumer demands that the industry is currently confronting.

We represent public and private companies, investment banks and venture capitalists in all aspects of the life sciences industry, including:

Read More

Leadership

Sort By
Redlick, David E.

David E. Redlick

Co-Chair, Life Sciences Group

+1 617 526 6434 (t)

david.redlick@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

Co-Chair, Life Sciences Group

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Experience

Our Life Sciences clients include:

Achillion Pharmaceuticals
Aspect Medical Systems
Becton Dickinson
Biogen Idec
Bio-Imaging Technologies
Boston Scientific
Curis
Cytogen
CollaGenex Pharmaceuticals
Genaissance Pharmaceuticals
Hybridon
IcagenIdenix Pharmaceuticals
IDEXX Laboratories
Infinity Pharmaceuticals
LipoScience
Millennium Pharmaceuticals
NitroMed
PAREXEL International
PerkinElmer
Senesco Technologies
Sepracor
Syngenta
Synthon Chiragenics
Thermo Electron
Transkaryotic Therapies
Wyeth

Publications & News

View

May 20, 2013

WilmerHale Lawyers, Practices Recognized by Chambers Europe 2013

In the 2013 edition of Chambers Europe: Leading Lawyers for Business, 20 WilmerHale lawyers and seven firm practices have been recognized as leading in their field.

April 17, 2013

Selected 2013 Life Sciences Transactions

Recognized both globally and nationally as a leading life sciences practice, WilmerHale has four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks.

April 5, 2013

Technical and Scientific Experience

Our ability to provide superior legal representation to technology companies is greatly enhanced by the academic and industry experience of our lawyers in a wide variety of technical and scientific fields.    

April 3, 2013

The 20th Annual BIO International Convention: We’ll See You in Chicago

The 20th annual BIO International Convention—the largest global event for the biotechnology industry, featuring keynote addresses and sessions led by key policymakers, scientists, CEOs and celebrities—will be taking place from April 22-25, 2013 in Chicago, Illinois.

March 14, 2013

WilmerHale Earns Top Rankings in BioPharm Insight’s 2012 League Tables

BioPharm Insight’s 2012 Licensing League Tables ranks WilmerHale as the leading legal advisor in its global and North America volume tables and lists the firm in fourth place in its global and North America value tables.

March 4, 2013

Planning for March 16, 2013: Important Considerations as US Moves to a First-Inventor-to-File System

The America Invents Act (AIA) has already brought extensive reforms to US patent law since it was signed into law on September 16, 2011. On March 16, 2013, perhaps the most publicized change will take place when the US officially moves from a “first-to-invent” to “first-inventor-to-file” system.

February 13, 2013

WilmerHale Client Oxford BioTherapeutics Nominated for 2013 Breakthrough Alliance Award™

February 5, 2013

Massachusetts Lawyers Weekly Names Bill Lee a Lawyer of the Year

Massachusetts Lawyers Weekly has named Bill Lee, current partner and former co-managing partner of the firm, a “2012 Lawyer of the Year.” Recognized for his marked success in 2012, Lee is featured in the January 21 issue in a Q&A piece in which he discusses the closely watched trial between Apple and Samsung that resulted in a $1.05 billion victory for his client.

January 24, 2013

HHS Issues Final Omnibus HIPAA Rule

January 7, 2013

Experienced Life Sciences Lawyer Rejoins WilmerHale’s Boston Office

WilmerHale is pleased to announce that Richard Hoffman will rejoin its Boston office as a partner in the Transactional Department and Corporate and Life Sciences Groups. He has more than 25 years of corporate, legal and business development experience in the life sciences industry. Mr. Hoffman has significant expertise in establishing new companies and advising existing companies on corporate, financial and business development strategies.